5 Pharmaceutical preparations for the treatment of fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and peroral formulations, tablets and capsules that facilitate the delivery of pharmaceutical preparations; pharmaceutical drugs for the treatment of fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and peroral formulations, tablets and capsules that facilitate the delivery of pharmaceutical preparations; Biochemical medicines for the treatment of fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; chemical preparations for pharmaceutical purposes, namely, for the treatment of fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; diagnostic agents for medical purposes; pharmaceutical substances and preparations for the treatment of fibrotic disease, liver fibrosis, kidney fibrosis, lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; carrier excipients consisting of compounds that facilitate delivery of pharmaceutical preparations